GlassScriptPhysician profile
Maybel M Tan
NPI 1053657684
$7,066.96
in general payments reported to CMS, 2019-2025
22 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $295 · 2021: $960 · 2022: $1,795 · 2023: $1,044 · 2024: $1,029 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,551 · Education: $79.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.74 |
| Education | $79.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,044.86 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $692.59 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $617.57 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Calliditas Therapeutics US INC. | $585.06 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $465.10 | 2021-2025 | Benlysta, Shingrix |
| Fresenius USA Marketing, INC. | $459.98 | 2019-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $413.84 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $389.65 | 2021-2025 | |
| Travere Therapeutics, INC. | $350.31 | 2022-2025 | |
| Vifor Pharma, INC. | $311.97 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $308.99 | 2019-2023 | Jynarque |
| Ardelyx, INC. | $287.54 | 2023-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $253.06 | 2023-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $220.35 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $143.61 | 2021-2025 | Rayaldee |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $135.02 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $113.97 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $109.41 | 2022-2024 | Acthar |
| Lilly USA, LLC | $81.55 | 2023-2024 | Mounjaro, Jardiance |
| Scpharmaceuticals INC. | $43.82 | 2025 | |
| Genzyme Corporation | $19.68 | 2021 | |
| Apellis Pharmaceuticals, INC. | $19.03 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maybel Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.